$OKLO

Cochran Caroline sold $819K of OKLO

Cochran Caroline (Co-Founder, COO) sold 12,600 shares of Oklo Inc. (OKLO) at $64.99 ($0.82M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cochran Caroline
Published Jun 2, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OKLO
Neutral
medium confidence
Mentioned
$OKLO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

Because the transaction is explicitly pre-arranged, it is less likely to represent new, non-public information. The main tradable element is short-term sentiment/positioning rather than fundamentals.

02

Market read

A disclosed insider sale (12,600 shares) with a 10b5-1 plan typically has limited fundamental implications but can slightly influence near-term sentiment.

03

What to watch

The filing doesn’t reveal motivations; the sale could be routine liquidity planning. Also, the market may already have priced the underlying sale window given the 10b5-1 structure.

Relevance 6/10Novelty 3/10Timing: After-hours/next-session read-through from the SEC Form 4 disclosure (sale dated 2026-06-01).

Background

The article is an SEC Form 4 insider transaction for Oklo, Inc., reporting an officer/director/10% owner sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo co-founder/COO and 10% owner Cochran Caroline sold 12,600 shares in an open-market transaction disclosed on Form 4.

Expected impact

Likely limited immediate price impact; any effect would be sentiment/positioning rather than a new fundamental catalyst.

Evidence & confidence

The filing specifies an open-market sale and confirms a pre-arranged 10b5-1 plan, reducing the likelihood of information leakage; the article provides no accompanying operational/financial change.

Market effects

Minimal—this is company-specific insider activity with no stated sector/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with valuation/financing considerations; traders may treat it as a mild bearish signal if selling frequency is elevated.

Key entities

  • Oklo Inc.

    Subject of the Form 4 insider transaction; co-founder/COO sold shares.

  • Cochran Caroline

    Oklo co-founder, COO, officer/director, and 10% owner who executed the sale.

Related articles

$OKLOMedAI 8/10

Oklo’s (OKLO) Groves Reactor Hits Criticality In Under A Year

Oklo Inc. (NYSE:OKLO) said its Groves Isotope Test Reactor in Lockhart, Texas, reached first criticality on Aug. 6, less than a year after groundbreaking. The company said it is the first Reactor Pilot Program project to reach criticality on private land from a greenfield site. Oklo reported a quarterly net loss of $81.6M and raised 2026 cash flow and capex guidance.

$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.